N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-2-fluoro-5-(4-methyl-piperazin-1-ylmethyl)-benzamide | 1108744-17-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-2-fluoro-5-(4-methyl-piperazin-1-ylmethyl)-benzamide
• 英文别名: N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-2-fluoro-5-[(4-methylpiperazin-1-yl)methyl]benzamide
• CAS: 1108744-17-7
• 化学式: C₂₇H₂₆F₃N₅O
• 分子量: 493.532
• InChiKey: HFTFKIPGVNJOEF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  36
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  64.3
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  N-甲基哌嗪 、 N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-2-fluoro-5-formyl-benzamide 在 溶剂黄146 、 三乙酰氧基硼氢化钠 、 氨 、 水 作用下， 以 四氢呋喃 、 乙酸乙酯 为溶剂， 反应 0.5h， 生成 N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-2-fluoro-5-(4-methyl-piperazin-1-ylmethyl)-benzamide
  参考文献：
  名称：

  [EN] SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS
  [FR] DÉRIVÉS D'INDAZOLE SUBSTITUÉS ACTIFS COMME INHIBITEURS DE KINASES

  摘要：

  公开了公式（I）的吲唑衍生物及其药用盐，如规范中定义的，以及它们的制备方法和包含它们的药物组合物；本发明的化合物可能在治疗与蛋白激酶活性失调相关的疾病，如癌症方面有用。

  公开号：

  WO2009013126A1

文献信息

• Molecules for administration to ROS1 mutant cancer cells
  申请人：Ignyta, Inc.

  公开号：US10231965B2

  公开（公告）日：2019-03-19

  Substituted indazole derivatives of formula (I) or formula 2.(I) and pharmaceutically acceptable salts thereof, as defined in the specification, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful in therapy in the treatment of diseases associated with a deregulated protein kinase activity, like cancer.

  公开了公式（I）或公式2的取代吲唑衍生物以及其药用盐，如规范中所定义，其制备方法和包含它们的药物组合物；该发明的化合物可能在治疗与蛋白激酶活性失调相关的疾病，如癌症方面有用。
• Substituted indazole derivatives active as kinase inhibitors
  申请人：Nerviano Medical Sciences S.R.L.

  公开号：US08299057B2

  公开（公告）日：2012-10-30

  Substituted indazole derivatives of formula (I) and pharmaceutically acceptable salts thereof, as defined in the specification, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful in therapy in the treatment of diseases associated with a deregulated protein kinase activity, like cancer.

  本发明公开了式(I)的取代吲唑衍生物及其药学上可接受的盐，以及其制备方法和包含它们的药物组合物；本发明的化合物可能在治疗与蛋白激酶活性失调相关的疾病，如癌症方面有用。
• SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS
  申请人：LOMBARDI BORGIA Andrea

  公开号：US20130018036A1

  公开（公告）日：2013-01-17

  Substituted indazole derivatives of formula (I) and pharmaceutically acceptable salts thereof, as defined in the specification, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful in therapy in the treatment of diseases associated with a deregulated protein kinase activity, like cancer.

  本发明披露了式（I）的取代吲唑衍生物及其药学上可接受的盐，其定义在说明书中，以及其制备过程和包含它们的制药组合物；本发明的化合物可能在治疗与蛋白激酶活性失调相关的疾病，如癌症中有用。
• N-[5-(3,5-DIFLUOROBENZYL)-1H-INDAZOL-3-YL]-4-(4-METHYL-PIPERAZIN-1-YL)-2-(TETRAHYDRO-2H-PYRAN-4-YLAMINO) BENZAMIDE FOR TREATING PATIENTS WITH ROS1,NTRK1, NTRK2 AND NTRK3 MUTANT CANCER CELLS
  申请人：Ignyta, Inc.

  公开号：EP3834827A1

  公开（公告）日：2021-06-16

  Substituted indazole derivatives of formula (I) or formula 2.(I) and pharmaceutically acceptable salts thereof, as defined in the specification, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful in therapy in the treatment of diseases associated with a deregulated protein kinase activity, like cancer.

  本发明公开了式(I)或式2.(I)的取代吲唑衍生物及其药学上可接受的盐类（如说明书中所定义）、其制备工艺和包含它们的药物组合物；本发明的化合物可用于治疗与蛋白激酶活性失调有关的疾病（如癌症）。
• Methods for treating neuroblastoma
  申请人：IGNYTA, INC.

  公开号：US10561651B2

  公开（公告）日：2020-02-18

  Methods of treating neuroblastoma associated with a deregulated protein kinase activity are disclosed. The treatment may include administration of substituted indazole derivatives of formula (I) or formula 2.(I) and pharmaceutically acceptable salts therefor, as degined in the specification.

  本发明公开了治疗与蛋白激酶活性失调有关的神经母细胞瘤的方法。治疗方法可包括施用式(I)或式2.(I) 的取代吲唑衍生物及其药学上可接受的盐类，如说明书所述。